The area of fixation covaries with short‐term changes in visual acuity after anti‐vascular endothelial growth factor treatment in patients with diabetic macular oedema

Purpose Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) England), 2018-11, Vol.96 (7), p.744-748
Main Authors: Jakobsen, Nanna Stæhr, Larsen, Dorte Ancher, Bek, Toke
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
anti‐VEGF treatment
Bevacizumab - therapeutic use
diabetic retinopathy
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - physiopathology
Female
Fixation, Ocular - physiology
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema - drug therapy
Macular Edema - physiopathology
macular oedema
Male
Middle Aged
Prospective Studies
Ranibizumab - therapeutic use
retinal fixation
Saccades - physiology
Vascular Endothelial Growth Factor A - antagonists & inhibitors
visual acuity
Visual Acuity - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those who will not. Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to macular disease, but the changes in fixational eye movements after anti‐VEGF treatment for diabetic maculopathy have not been investigated. Methods Retinal fixation was studied in 29 patients with diabetic macular oedema before three monthly anti‐VEGF injections, and 1 and 4 months after the last injection. The change in VA was correlated with changes in area, frequency, amplitude and total number of fixational saccades. Results During three monthly injections, best‐corrected visual acuity (BCVA) increased from (mean ± SD) 74.0 ± 11.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters to 78.3 ± 9.8 ETDRS letters, (p = 0.003) and central retinal thickness (CRT) decreased from (mean ± SD) 441.7 ± 107.0 μm to 339.5 ± 74.2 μm, (p = 
ISSN:1755-375X
1755-3768
DOI:10.1111/aos.13773